Study of CM313 injection for platelet transfusion resistance
Part of Blood & lymphatic clinical trials.
This trial tests a new drug called CM313 to see if it can help people whose platelet transfusions stop working. It is for adults who need platelet transfusions and have developed antibodies against them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must need regular platelet transfusions and they no longer work well
- You must have at least one type of antibody against platelets in your blood
- You must be 18 years or older
- You must be well enough to walk around and take care of yourself (ECOG score 2 or less)
- You cannot have a condition called immune thrombocytopenia (ITP)
- You cannot have a non-immune reason for your platelets not responding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called CM313 for people with aplastic anemia that has returned or not responded to other treatments. It aims to see if CM313 can help improve blood cell counts.
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
This trial tests a new antibody treatment (anti-CD38) for children ages 6 to 18 who have had low platelets for at least 3 months and did not improve with steroids. The goal is to see if this treatment can safely raise platelet counts.
This trial tests an anti-CD38 antibody in people with antiphospholipid syndrome (APS) who have very low platelet counts and haven't improved with steroids or other treatments. The goal is to see if it can safely raise platelet levels.
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
This trial tests an investigational drug called CID-103 for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. It aims to find the right dose and see if it can safely increase platelet counts to reduce bleeding risk.
Hear when a new Platelet Transfusion Refractoriness trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.